Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published evidence and current clinical practice at FMRI Gurugram.
Introduction
The classical model of prostate cancer treats metastatic disease as a systemic problem from the moment it is diagnosed. Androgen deprivation therapy (ADT), often combined with a novel hormonal agent or chemotherapy, is delivered systemically — affecting cancer cells wherever they are, but also affecting the whole patient with the side-effect profile that systemic therapy brings.
The oligometastatic concept challenges this model in a specific clinical setting. When prostate cancer has spread to only a handful of detectable sites — typically defined as five or fewer metastases on PSMA PET-CT — the disease may behave biologically differently from widely metastatic disease. The question this raises is whether directly treating those specific sites (with surgery, stereotactic radiotherapy, or in selected cases targeted radioligand therapy) can delay or defer systemic therapy and its side effects, and perhaps improve disease control. This guide walks through where metastasis-directed Lu-177 PSMA therapy fits into that question.
How it differs from systemic Lu-PSMA therapy
The mechanism of Lu-177 PSMA is identical whether the patient has oligometastatic or widely metastatic disease — the same molecule, the same isotope, the same delivery route. What differs is the clinical setting in which it is given and the expected outcomes. In widely metastatic disease, Lu-PSMA is given as a recognised systemic therapy in a defined treatment line; the goal is disease control and prolongation of survival. In oligometastatic disease, the goal is more about deferring the start of long-term systemic therapy (ADT and its consequences) and producing local control of each visible metastasis. The treatment course may be shorter, the dosimetry may differ, and the follow-up imaging schedule may be tighter.
This is a clinical strategy that needs careful discussion with the patient. For some men, the option to defer ADT for additional months or years is a quality-of-life consideration with real weight. For others, the priority is to start the most established systemic therapy and adjust if needed. There is no single right answer.
Where the evidence stands
The clearest randomised evidence for any form of metastasis-directed therapy in oligometastatic prostate cancer comes from the SBRT trials — STOMP and ORIOLE — both of which demonstrated that SBRT to oligometastatic deposits delayed the time to systemic therapy initiation compared with surveillance. The role of Lu-PSMA specifically in oligometastatic disease has been studied in smaller series and is the subject of ongoing trials. Available data is encouraging but not yet at the level of randomised phase III evidence.
The honest framing is therefore: metastasis-directed Lu-PSMA in oligometastatic disease is a clinically reasonable strategy in selected patients, delivered in a centre with the experience to assess eligibility and counsel honestly about uncertainties. It is not a proven standard with the same evidence base as systemic Lu-PSMA in mCRPC.
How we approach the decision at FMRI
At FMRI Gurugram, every oligometastatic prostate cancer patient considering metastasis-directed Lu-PSMA goes through a structured multidisciplinary review involving the urologist, radiation oncologist, medical oncologist, and nuclear medicine physician. The discussion covers: the most appropriate form of metastasis-directed therapy (SBRT, surgery to specific deposits, or Lu-PSMA — sometimes a combination); the timing of systemic therapy initiation; the patient's priorities for quality of life; and the realistic conversation about evidence strength and uncertainty.
If you or a loved one is considering metastasis-directed Lu-PSMA therapy, the most useful preparation is to bring a recent PSMA PET-CT (within the last six weeks if possible), the original diagnosis and treatment history, recent PSA values, recent kidney function and full blood count results, and any prior local therapy details. With this information, an individualised plan can be discussed in detail. We will give you an honest assessment of what is known and what is not — and the decision is yours.
For patients & referring clinicians
Frequently asked questions
Q01
What is oligometastatic prostate cancer?
Oligometastatic prostate cancer typically refers to disease with five or fewer metastatic sites on imaging — generally without visceral metastases. The most modern definitions anchor the count to PSMA PET-CT findings, since this scan detects more metastases than conventional bone scan plus CT. The distinction between synchronous oligometastatic disease (at first presentation) and metachronous oligometastatic disease (relapse after prior local therapy) is also clinically important.
Q02
What is metastasis-directed therapy?
Metastasis-directed therapy is a strategy of treating each visible metastatic deposit directly — by stereotactic body radiation therapy (SBRT), surgery, or in selected cases targeted radioligand therapy — rather than (or in addition to) starting systemic therapy. The rationale is that targeting visible deposits may delay disease progression, defer the start of long-term systemic therapy, and improve quality of life. Randomised trials (STOMP, ORIOLE) have shown that SBRT to oligometastatic deposits can delay the time to systemic therapy initiation.
Q03
Why might Lu-PSMA be used in oligometastatic disease?
Lu-PSMA radioligand therapy delivers a targeted radiation dose to every PSMA-expressing tumour deposit across the body. In oligometastatic disease, where the number of deposits is small but each is PSMA-positive, a single course may provide systemic coverage of every visible site. The clinical reasoning is to extend the metastasis-directed strategy from local techniques like SBRT to a body-wide molecular approach. It is an emerging strategy, not a fully established standard.
Q04
Who qualifies?
At FMRI, we consider metastasis-directed Lu-PSMA in oligometastatic disease when the following apply: metachronous oligometastatic prostate cancer (relapse after prior radical therapy), five or fewer PSMA-positive metastases on PSMA PET-CT, no visceral metastases, adequate kidney and bone marrow function, performance status appropriate for radioligand therapy, and a multidisciplinary review that concludes Lu-PSMA is a reasonable strategy alongside the alternatives (SBRT, surveillance, or systemic therapy).
Q05
How does this compare with systemic Lu-PSMA therapy for advanced disease?
The mechanism is identical — the same molecule binds the same PSMA target and delivers the same Lutetium-177 radiation. What differs is the clinical setting and the goal. Systemic Lu-PSMA in metastatic castration-resistant prostate cancer is a recognised, FDA-approved indication backed by the VISION trial. Lu-PSMA in oligometastatic disease is an emerging strategy supported by mechanism and observational experience, not yet by definitive randomised phase III evidence in this specific setting.
Q06
Does this replace ADT?
Not necessarily. In some oligometastatic patients, metastasis-directed therapy is used together with intermittent or deferred ADT. In others, it is used to defer ADT initiation by months or years. The right combination depends on the disease pattern, the patient's priorities, and the multidisciplinary judgment about timing. The decision is individualised — there is no single algorithm that fits all oligometastatic patients.
Q07
What is the evidence strength?
For metastasis-directed therapy in oligometastatic prostate cancer broadly, randomised trial evidence supports SBRT (STOMP, ORIOLE) in delaying systemic therapy initiation. For metastasis-directed Lu-PSMA specifically, the evidence is at an earlier stage — smaller series, ongoing trials, and extrapolation from the strong evidence for systemic Lu-PSMA in mCRPC. The honest framing is: a clinically reasonable strategy in selected patients with realistic counselling about evidence strength.
Citations & references
Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION).
N Engl J Med. 2021;385(12):1091-1103.
ReferencePhillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2020;6(5):650-659.
Reference
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.